Consequences of POR mutations and polymorphisms

Molecular and Cellular Endocrinology

Volumn 336, Issue 1-2, 2011, Pages 174-179

  Miller, Walter L ^a   Agrawal, Vishal ^a   Sandee, Duanpen ^a   Tee, Meng Kian ^a   Huang, Ningwu ^a   Choi, Ji Ha ^b   Morrissey, Kari ^b   Giacomini, Kathleen M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CYP2D6; CYP3A4; Cytochrome P450; Drug metabolism; Enzyme kinetics; P450 oxidoreductase; Pharmacogenetics; Steroidogenesis

Indexed keywords

AROMATASE; CYTOCHROME C; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; CYTOCHROME P450C17; DEXTROMETHORPHAN; ERYTHROMYCIN; ESTROGEN RECEPTOR ALPHA; MIDAZOLAM; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SMAD3 PROTEIN; SMAD4 PROTEIN; STEROID 21 MONOOXYGENASE; TESTOSTERONE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA;

ANTLEY BIXLER SYNDROME; ASIAN; CAUCASIAN; DRUG METABOLISM; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME CONFORMATION; ENZYME METABOLISM; ENZYME SUBSTRATE; ETHNIC DIFFERENCE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENITAL MALFORMATION; HUMAN; JAPANESE; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; STEROIDOGENESIS; TRANSCRIPTION REGULATION; WILD TYPE;

CONGENITAL ABNORMALITIES; DISORDERS OF SEX DEVELOPMENT; HUMANS; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 79952068290     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.10.022     Document Type: Review

References (54)

1. Adachi M., Tachibana K., Asakura Y., Yamamoto T., Hanaki K., Oka A. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am. J. Med. Genet. A 2004, 128A:333-339.
2. Agrawal V., Choi J.H., Giacomini K.M., Miller W.L. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet. Genomics 2010, 20:611-618.
3. Agrawal V., Huang N., Miller W.L. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics 2008, 18:569-576.
4. Aguilar A., Wu S., De Luca F. P450 oxidoreductase (POR) expressed in rat chondrocytes modulates chondrogenesis via cholesterol- and Indian hedgehog (Ihh)-dependent mechanisms. Endocrinology 2009, 150:2732-2739.
5. Aleck K.A., Bartley D.L. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am. J. Med. Genet. 1997, 72:253-256.
6. Arlt W., Walker E.A., Draper N., Ivison H.E., Ride J.P., Hammer F., Chalder S.M., et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. The Lancet 2004, 363:2128-2135.
7. Auchus R.J. The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab. 2004, 15:432-438.
8. Cooper M.K., Wassif C.A., Krakowiak P.A., Taipale J., Gong R., Kelley R.I., Porter F.D., et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat. Genet. 2003, 33:508-513.
9. Debeljak N., Fink M., Rozman D. Many facets of mammalian lanosterol 14alpha-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch. Biochem. Biophys. 2003, 409:159-171.
10. Ekroos M., Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13682-13687.
11. Ellis J., Gutierrez A., Barsukov I.L., Huang W.C., Grossmann J.G., Roberts G.C. Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle X-ray scattering. J. Biol. Chem. 2009, 284:36628-36637.
12. Enoch H.G., Strittmatter P. Cytochrome b5 reduction by NADPH-cytochrome P-450 reductase. J. Biol. Chem. 1979, 254:8976-8981.
13. Evans W.E., McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, 348:538-549.
14. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
15. Fluck C.E., Miller W.L. P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia. Curr. Opin. Pediatr. 2006, 18:435-441.
16. Fluck C.E., Mullis P.E., Pandey A.V. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem. Biophys. Res. Commun. 2010, 401:149-153.
17. Fluck C.E., Tajima T., Pandey A.V., Arlt W., Okuhara K., Verge C.F., Jabs E.W., et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 2004, 36:228-230.
18. Fukami M., Hasegawa T., Horikawa R., Ohashi T., Nishimura G., Homma K., Ogata T. Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr. Res. 2006, 59:276-280.
19. Fukami M., Horikawa R., Nagai T., Tanaka T., Naiki Y., Sato N., Okuyama T., et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J. Clin. Endocrinol. Metab. 2005, 90:414-426.
20. Geller D.H., Auchus R.J., Mendonca B.B., Miller W.L. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat. Genet. 1997, 17:201-205.
21. Geller D.H., Auchus R.J., Miller W.L. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol. Endocrinol. 1999, 13:167-175.
22. Gofflot F., Hars C., Illien F., Chevy F., Wolf C., Picard J.J., Roux C. Molecular mechanisms underlying limb anomalies associated with cholesterol deficiency during gestation: implications of Hedgehog signaling. Hum. Mol. Genet. 2003, 12:1187-1198.
23. Gomes L.G., Huang N., Agrawal V., Mendonca B.B., Bachega T.A., Miller W.L. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 2008, 93:2913-2916.
24. Gu J., Weng Y., Zhang Q.Y., Cui H., Behr M., Wu L., Yang W., et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 2003, 278:25895-25901.
25. Henderson C.J., Otto D.M., Carrie D., Magnuson M.A., McLaren A.W., Rosewell I., Wolf C.R. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 2003, 278:13480-13486.
26. Hershkovitz E., Parvari R., Wudy S.A., Hartmann M.F., Gomes L.G., Loewental N., Miller W.L. Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. J. Clin. Endocrinol. Metab. 2008, 93:3584-3588.
27. Homma K., Hasegawa T., Nagai T., Adachi M., Horikawa R., Fujiwara I., Tajima T., et al. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J. Clin. Endocrinol. Metab. 2006, 91:2643-2649.
28. Huang N., Agrawal V., Giacomini K.M., Miller W.L. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:1733-1738.
29. Huang N., Pandey A.V., Agrawal V., Reardon W., Lapunzina P.D., Mowat D., Jabs E.W., et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 2005, 76:729-749.
30. Ilan Z., Ilan R., Cinti D.L. Evidence for a new physiological role of hepatic NADPH:ferricytochrome (P-450) oxidoreductase. Direct electron input to the microsomal fatty acid chain elongation system. J. Biol. Chem. 1981, 256:10066-10072.
31. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002, 181-182:447-452.
32. Kelley R.I., Kratz L.E., Glaser R.L., Netzloff M.L., Wolf L.M., Jabs E.W. Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am. J. Med. Genet. 2002, 110:95-102.
33. Li H.C., Liu D., Waxman D.J. Transcriptional induction of hepatic NADPH: cytochrome P450 oxidoreductase by thyroid hormone. Mol. Pharmacol. 2001, 59:987-995.
34. Miller W.L. Minireview: Regulation of steroidogenesis by electron transfer. Endocrinology 2005, 146:2544-2550.
35. Nicolo C., Fluck C.E., Mullis P.E., Pandey A.V. Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol. Cell. Endocrinol. 2010, 321:245-252.
36. Oneda B., Crettol S., Sirot E.J., Bochud M., Ansermot N., Eap C.B. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet. Genomics 2009, 19:877-883.
37. Ono T., Bloch K. Solubilization and partial characterization of rat liver squalene epoxidase. J. Biol. Chem. 1975, 250:1571-1579.
38. Otto D.M., Henderson C.J., Carrie D., Davey M., Gundersen T.E., Blomhoff R., Adams R.H., et al. Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol. Cell. Biol. 2003, 23:6103-6116.
39. Pandey A.V., Kempna P., Hofer G., Mullis P.E., Fluck C.E. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol. Endocrinol. 2007, 21:2579-2595.
40. Pursley T.J., Blomquist I.K., Abraham J., Andersen H.F., Bartley J.A. Fluconazole-induced congenital anomalies in three infants. Clin. Infect. Dis. 1996, 22:336-340.
41. Ram P.A., Waxman D.J. Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms. J. Biol. Chem. 1992, 267:3294-3301.
42. Sahakitrungruang T., Huang N., Tee M.K., Agrawal V., Russell W.E., Crock P., Murphy N., et al. Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients. J. Clin. Endocrinol. Metab. 2009, 94:4992-5000.
43. Sandee D., Morrissey K., Agrawal V., Tam H.K., Kramer M.A., Tracy T.S., Giacomini K.M., et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet. Genomics 2010, 20:677-686.
44. Schmidt K., Hughes C., Chudek J.A., Goodyear S.R., Aspden R.M., Talbot R., Gundersen T.E., et al. Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb. Mol. Cell. Biol. 2009, 29:2716-2729.
45. Scott R.R., Gomes L.G., Huang N.W., Van Vliet G., Miller W.L. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 2007, 92:2318-2322.
46. Scott R.R., Miller W.L. Genetic and clinical features of P450 oxidoreductase deficiency. Horm. Res. 2008, 69:266-275.
47. Shackleton C., Marcos J., Arlt W., Hauffa B.P. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am. J. Med. Genet. A 2004, 129A:105-112.
48. Shen A.L., O'Leary K.A., Kasper C.B. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J. Biol. Chem. 2002, 277:6536-6541.
49. Tee, M.K., Huang, N., Damm, I., Miller, W.L., submitted for publication. Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms.
50. Wang M., Roberts D.L., Paschke R., Shea T.M., Masters B.S., Kim J.J. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:8411-8416.
51. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 2003, 348:529-537.
52. Wilks A., Black S.M., Miller W.L., Ortiz de Montellano P.R. Expression and characterization of truncated human heme oxygenase (hHO-1) and a fusion protein of hHO-1 with human cytochrome P450 reductase. Biochemistry 1995, 34:4421-4427.
53. Williams P.A., Cosme J., Vinkovic D.M., Ward A., Angove H.C., Day P.J., Vonrhein C., et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004, 305:683-686.
54. Yamano S., Aoyama T., McBride O.W., Hardwick J.P., Gelboin H.V., Gonzalez F.J. Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7. Mol. Pharmacol. 1989, 36:83-88.